Cosponsor
Sign in

HR 1405 · in committee · niche

Enhancing Domestic Drug Manufacturing Competitiveness Act

What this bill does

  • The bill requires the Government Accountability Office to study regulatory barriers to pharmaceutical manufacturing in the United States.
  • It affects pharmaceutical manufacturers, environmental regulators, and Congress as it examines how rules impact drug production facilities.
  • The GAO will report findings and recommendations on streamlining regulations to improve U.S. competitiveness in drug manufacturing.

Generated by claude-haiku-4-5

Community Threads

Started by Cosponsor

  1. 01

    What specific regulatory barriers does the GAO study need to identify to help Congress decide which rules should be streamlined versus maintained?

  2. 02

    How might reducing environmental or safety regulations to boost domestic drug manufacturing affect pharmaceutical workers and communities near production facilities?

  3. 03

    If the U.S. increases drug manufacturing capacity through regulatory changes, who benefits most and what trade-offs might emerge in other industries?

Cosponsor writes these to seed civic discussion — they aren't user posts. Sign in to reply.

Sponsor · R-FL-16

Vern Buchanan

Citizen cosponsors

0

In Congress

1/ 435

House Reps cosponsoring

Introduced 2025-02-18

Joining the bill

Legislative timeline

  1. 2025-02-18 · house · IntroReferral

    Referred to the House Committee on Energy and Commerce.

  2. 2025-02-18 · IntroReferral

    Introduced in House

  3. 2025-02-18 · IntroReferral

    Introduced in House

Congress.gov ↗

Citizen comments

Sign in to comment on this bill.

No comments yet — be the first.